Lannett gets notice probe into alleged generic drug price-fixing may widen


The Northeast Philadelphia generic drug maker said it received written notice from various state Attorneys General that they intend to bring claims alleging price fixing and anti-competitive behavior involving more drug products.

Previous Daemen College responds to uptick in healthcare-related majors
Next Local health system launches digital engagement division